Methods for the evaluation of the effectiveness and cost-effectiveness of new drugs, technologies and health policies from large observational data.
Our researchers are developing, evaluating and applying methods for health economic studies that use large routine observational datasets. Our methodological interests include: harnessing observational data to improve the external validity of trials, and improving methods for handling confounding and missing data. We have experience in using large routine data sources such as Patient Reported Outcomes Measures (PROMs), and Hospital Episode Statistics (HES), to evaluate new technologies and health policies of national and international policy-relevance.
Our future plans include evaluating new pharmaceuticals, technologies and health service changes using electronic health records such as Clinical Practice Research Datalink (CPRD), linked to disease registers, for example for cancer and rheumatic diseases. In undertaking these evaluations we work with national policy-makers such as the Department of Health and NICE.
For further details, please see our website, follow us on twitter @THETA_lshtm
or contact: email@example.com, firstname.lastname@example.org or email@example.com